



**Fueling the practice of  
non-invasive interventional glaucoma**

\* ViaLase products are currently not for sale, pending regulatory clearance

# The ViaLase Solution

ViaLase technology addresses a large unmet need for a non-surgical, non-pharmacologic intervention for patients suffering from glaucoma



Compelling Clinical Evidence



Non-invasive, non-surgical Procedure




Seamless Doctor & Patient Experience



Superior Visualization

# Introducing The ViaLuxe™ Laser System & “FLIGHT”

Reduce IOP using a micron accurate femtosecond laser **to noninvasively create precise drainage channels** in the trabecular meshwork



# Components of ViaLuxe™ Laser System

## ViaLuxe™




Laser System incorporating proprietary components femtosecond laser engine and electronics, micron accurate OCT, graphic user interface (GUI) and touchscreen

## ViaVue™



Hand-held, high definition gonio camera Allows you to predictably identify and select your desired treatment location, all without applying suction to the eye



## ViaLens™




Single use patient interface enables precise delivery of laser pulses into the trabecular meshwork while eliminating unwanted corneal distortions

# ViaLase Key Points of Differentiation

- ▶ **Noninvasive:** Femtosecond laser creates a precisely defined channel without opening up the eye thus mitigating risk associated with incisional procedures
- ▶ **Superior Visualization:** HD gonioscopic & micron-accurate OCT imaging overcome traditional visualization limitations
- ▶ **Individualized Approach:** Treatment is programmable to access all four quadrants, nasal and temporal areas alike
- ▶ **Broad Indication:** Performed outside of cataract surgery, a common – and limiting – requirement for MIGS procedures



# First-In-Human Safety Study of FLIGHT: 24-month Outcomes



Nagy Z.Z., Kranitz K., Ahmed I.I.K., De Francesco T., Mikula E. & Juhasz T., First-in-Human Safety Study of Femtosecond Laser Image Guided Trabeculotomy for Glaucoma Treatment: 24-month Outcomes, Ophthalmology Science (2023)

- ▶ **Single-channel (500 x 200 $\mu$ ) treatment, no washout (N = 18)**
- ▶ **No serious adverse events** related to FLIGHT treatment at any timepoint
- ▶ **34.6% mean IOP reduction** at 24 mos

<b>At 24 Months</b>	<b>Mean IOP</b>	<ul style="list-style-type: none"> <li>• 88% percent of eyes achieved IOP <math>\leq</math> 18 mmHg</li> </ul>
	<b>Responder Rate</b>	<ul style="list-style-type: none"> <li>• 82% percent of eyes achieved more than 20% IOP reduction (53% of patients achieved 25% or more)</li> </ul>

# Summary



ViaLase is a med-tech startup company with the **Mission to fuel the practice of non-invasive interventional glaucoma**



The **non-invasive** ViaLuxe Laser System is designed to combine **micron accurate OCT** and **precision of femtosecond laser** for treatment of glaucoma



24 month first-in-human study demonstrates an **excellent safety** profile and **durable IOP reduction**



ViaLase is preparing for registration of both **CE Mark and FDA 510k Clearance** and subsequent commercial launch



**Thank You**

